R C Petersen

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
  2. pmc Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications
    Mariet Allen
    Mayo Clinic Florida, Department of Neuroscience, Jacksonville, FL, USA
    Mol Neurodegener 7:13. 2012
  3. pmc Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging
    R C Petersen
    Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 75:889-97. 2010
  4. pmc Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization
    R C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 74:201-9. 2010
  5. pmc Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy
    Ronald C Petersen
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 4:S88-90. 2008
  6. ncbi Mild cognitive impairment clinical trials
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Nat Rev Drug Discov 2:646-53. 2003
  7. ncbi Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment
    R C Petersen
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Nutr Health Aging 14:304-5. 2010
  8. ncbi Neuropathologic features of amnestic mild cognitive impairment
    Ronald C Petersen
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:665-72. 2006
  9. ncbi Mild cognitive impairment: an overview
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    CNS Spectr 13:45-53. 2008
  10. ncbi Mild cognitive impairment: is it Alzheimer's disease or not?
    Ronald C Petersen
    Mayo Alzheimer s Disease Research Center Mayo Clinic College of Medicine, Rochester, MN, USA
    J Alzheimers Dis 7:241-5; discussion 255-62. 2005

Research Grants

  1. ALZHEIMER DISEASE PATIENT REGISTRY
    Ronald Petersen; Fiscal Year: 2007

Detail Information

Publications162 found, 100 shown here

  1. pmc TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease
    Sruti Rayaprolu
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Mol Neurodegener 8:19. 2013
    ..With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders...
  2. pmc Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications
    Mariet Allen
    Mayo Clinic Florida, Department of Neuroscience, Jacksonville, FL, USA
    Mol Neurodegener 7:13. 2012
    ..4,617 controls) and PD (678 PDs vs. 712 controls) for association with disease risk (case-controls), age-at-diagnosis (cases) and brain gene expression levels (autopsied subjects)...
  3. pmc Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging
    R C Petersen
    Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 75:889-97. 2010
    ..We investigated the prevalence of mild cognitive impairment (MCI) in Olmsted County, MN, using in-person evaluations and published criteria...
  4. pmc Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization
    R C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 74:201-9. 2010
    ..Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally...
  5. pmc Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy
    Ronald C Petersen
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Alzheimers Dement 4:S88-90. 2008
  6. ncbi Mild cognitive impairment clinical trials
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Nat Rev Drug Discov 2:646-53. 2003
  7. ncbi Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment
    R C Petersen
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Nutr Health Aging 14:304-5. 2010
    ..It is proposed that the clinical criteria for mild cognitive impairment be enriched with imaging and other biomarkers to improve the specificity of the outcome, and these criteria might suffice for pre-dementia clinical trials...
  8. ncbi Neuropathologic features of amnestic mild cognitive impairment
    Ronald C Petersen
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:665-72. 2006
    ..The neuropathologic substrate of amnestic mild cognitive impairment (aMCI) is not known...
  9. ncbi Mild cognitive impairment: an overview
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    CNS Spectr 13:45-53. 2008
    ..The recently completed clinical trials as well as neuropsychological and nutritional interventions are discussed. Finally, the clinical utility of MCI, and directions for future research are proposed...
  10. ncbi Mild cognitive impairment: is it Alzheimer's disease or not?
    Ronald C Petersen
    Mayo Alzheimer s Disease Research Center Mayo Clinic College of Medicine, Rochester, MN, USA
    J Alzheimers Dis 7:241-5; discussion 255-62. 2005
  11. ncbi Mild cognitive impairment as a clinical entity and treatment target
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Arch Neurol 62:1160-3; discussion 1167. 2005
  12. pmc Mild cognitive impairment: ten years later
    Ronald C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arch Neurol 66:1447-55. 2009
    ..This review summarizes the progress that has been made while also recognizing the challenges that remain...
  13. ncbi Mild cognitive impairment: where are we?
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minnesota, 55905, USA
    Alzheimer Dis Assoc Disord 19:166-9. 2005
  14. ncbi The current status of mild cognitive impairment--what do we tell our patients?
    Ronald C Petersen
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, 200 First Street South West, Rochester, MN 55905, USA
    Nat Clin Pract Neurol 3:60-1. 2007
  15. ncbi Mild cognitive impairment should be considered for DSM-V
    Ronald C Petersen
    Mayo Clinic College of Medicine, Department of Neurology, Rochester, MN 55905, USA
    J Geriatr Psychiatry Neurol 19:147-54. 2006
    ..Future research directions to help clarify some of the remaining uncertainties are proposed...
  16. ncbi Conversion
    Ronald C Petersen
    Department of Neurology and the Mayo Alzheimer Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Neurology 67:S12-3. 2006
    ....
  17. pmc Early diagnosis of Alzheimer's disease: is MCI too late?
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Curr Alzheimer Res 6:324-30. 2009
    ..The neuropathology of MCI is intermediate between the neuropathologic changes of aging and fully developed Alzheimer's disease. The breadth of research in MCI is expanding and will be reviewed...
  18. pmc Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment
    R C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Pharmacol Ther 86:438-41. 2009
    ..Ultimately, it is likely that the use of a combination of neuroimaging and chemical biomarkers will be involved in predicting the development of dementia and Alzheimer's disease (AD)...
  19. ncbi Mild cognitive impairment: transition between aging and Alzheimer's disease
    R C Petersen
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Mayo Clinic, Rochester, MN, USA
    Neurologia 15:93-101. 2000
    ..Mild cognitive impairment is an important topic for research in aging and dementia and has also become the subject of several multicenter treatment trials...
  20. ncbi Current concepts in mild cognitive impairment
    R C Petersen
    Department of Neurology, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 58:1985-92. 2001
    ..While no treatments are recommended for MCI currently, clinical trials regarding potential therapies are under way. Recommendations concerning ethical issues in the diagnosis and the management of subjects with MCI were made...
  21. ncbi Aging, mild cognitive impairment, and Alzheimer's disease
    R C Petersen
    Alzheimer Disease Research Center, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurol Clin 18:789-806. 2000
    ....
  22. ncbi MCI is a clinically useful concept
    Ronald C Petersen
    Alzheimer s Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN, USA
    Int Psychogeriatr 18:394-402; discussion 409-14. 2006
  23. pmc Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS
    K Kantarci
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 72:1519-25. 2009
    ..To investigate the combined ability of hippocampal volumes, 1H magnetic resonance spectroscopy (MRS) metabolites, and cerebrovascular disease to predict the risk of progression to dementia in mild cognitive impairment (MCI)...
  24. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:294-301. 2009
    ....
  25. pmc MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 73:287-93. 2009
    ..To assess the correlations of both MRI and CSF biomarkers with clinical diagnosis and with cognitive performance in cognitively normal (CN) subjects and patients with amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD)...
  26. pmc Serial MRI and CSF biomarkers in normal aging, MCI, and AD
    P Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 75:143-51. 2010
    ..Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials...
  27. pmc DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 64:902-4. 2005
    ..002). Magnetic resonance diffusion-weighted imaging may help identify patients with aMCI who will progress to AD as well as or better than structural MRI measures of hippocampal atrophy...
  28. pmc Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester MN 55905, USA
    Neurology 74:1279-87. 2010
    ..To use diffusion tensor imaging (DTI) to assess gray matter and white matter tract diffusion in behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SMD), and progressive nonfluent aphasia (PNFA)...
  29. pmc Atrophy rates accelerate in amnestic mild cognitive impairment
    C R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 70:1740-52. 2008
    ..We included comparisons to subjects with aMCI who did not progress (labeled aMCI-S) and also to cognitively normal elderly subjects (CN)...
  30. pmc Two distinct subtypes of right temporal variant frontotemporal dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1443-50. 2009
    ..We aimed to determine whether right temporal FTD is a homogeneous clinical, imaging, and pathologic/genetic entity...
  31. pmc Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:1850-7. 2008
    ....
  32. pmc Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
    D S Knopman
    Department of Neurology, Mayo Clinic Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 78:1576-82. 2012
    ..Stage 0, not explicitly defined in the criteria, represents subjects with normal biomarkers and normal cognition. The ability of the recommended criteria to predict progression to cognitive impairment is the crux of their validity...
  33. pmc APOE modifies the association between Aβ load and cognition in cognitively normal older adults
    K Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 78:232-40. 2012
    ..To determine the relationship between β-amyloid (Aβ) load as measured by [(11)C]-Pittsburgh compound B (PiB) PET and cognitive function in cognitively normal older adults...
  34. pmc The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging
    R O Roberts
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Neurology 78:342-51. 2012
    ..We estimated the incidence of amnestic MCI (aMCI) and nonamnestic MCI (naMCI) in men and women separately...
  35. ncbi Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP
    K A Josephs
    Division of Movement Disorders, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 66:41-8. 2006
    ..To examine the relationship between early clinical features, pathologies, and biochemistry of the frontotemporal lobar degenerations (FTLDs), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)...
  36. pmc Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 77:393-8. 2011
    ..To use multiple serial MRI to assess rates and trajectories of brain and hippocampal atrophy in subjects with frontotemporal dementia (FTD) with progranulin (GRN) or microtubule-associated protein tau (MAPT) gene mutations...
  37. pmc Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 55:484-89. 2000
    ..69%, AD 3. 5%. CONCLUSION: Rates of hippocampal atrophy match both baseline cognitive status and the change in cognitive status over time in elderly persons who lie along the cognitive continuum from normal to MCI to AD...
  38. pmc MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology
    K Kantarci
    Departmentsof Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:771-8. 2010
    ..To determine the proton magnetic resonance spectroscopy ((1)H MRS) changes in carriers of microtubule-associated protein (MAPT) mutations in a case-control study...
  39. pmc Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
    C R Jack
    Department of Diagnostic Radiology and MR Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 62:591-600. 2004
    ....
  40. ncbi Neuropathology of cognitively normal elderly
    D S Knopman
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Neuropathol Exp Neurol 62:1087-95. 2003
    ..The few subjects with more severe AD pathology can be expected based on incidence rates of AD in the very elderly...
  41. pmc Diffusion tensor imaging and cognitive function in older adults with no dementia
    K Kantarci
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 77:26-34. 2011
    ..To determine the patterns of diffusivity associated with cognitive domain functions in older adults without dementia...
  42. pmc Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 73:1058-65. 2009
    ..To use a case-control study to assess and compare patterns of gray matter loss across groups of subjects with different mutations in the microtubule-associated protein tau (MAPT) gene...
  43. pmc Caudate atrophy on MRI is a characteristic feature of FTLD-FUS
    K A Josephs
    Department of Neurology Behavioral Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Neurol 17:969-75. 2010
    ..We have observed severe caudate atrophy at autopsy in FTLD-FUS, and hence, we aimed to determine whether caudate atrophy on MRI is a feature that can distinguish FTLD-FUS from FTLD-TDP and FTLD-TAU...
  44. pmc Age-related changes in the default mode network are more advanced in Alzheimer disease
    D T Jones
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 77:1524-31. 2011
    ..To investigate age-related default mode network (DMN) connectivity in a large cognitively normal elderly cohort and in patients with Alzheimer disease (AD) compared with age-, gender-, and education-matched controls...
  45. ncbi Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey-Osterrieth Complex Figure
    M M Machulda
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Exp Neuropsychol 29:377-84. 2007
    ..Limitations and unique features of the MOANS normative data are also discussed...
  46. ncbi Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology
    G A Rippon
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurocase 11:204-11. 2005
    ..We suggest that PSP with or without coexisting AD and AGD be included in the differential diagnosis of patients presenting with FTD...
  47. ncbi A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?
    G E Smith
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 69:133-9. 2007
    ..To compare logistic and bilogistic models to describe the pattern of cognitive decline in the preclinical phase of Alzheimer disease (AD)...
  48. ncbi Mortality in amnestic mild cognitive impairment: a prospective community study
    A L Hunderfund
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 67:1764-8. 2006
    ..To assess the hazard of death in persons with and without amnestic mild cognitive impairment (aMCI)...
  49. pmc MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neurology 70:512-20. 2008
    ..To compare the patterns of gray matter loss in subjects with amnestic mild cognitive impairment (aMCI) who progress to Alzheimer disease (AD) within a fixed clinical follow-up time vs those who remain stable...
  50. pmc Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 52:1397-403. 1999
    ..CONCLUSION: In older patients with MCI, hippocampal atrophy determined by premorbid MRI-based volume measurements is predictive of subsequent conversion to AD...
  51. pmc The anatomic correlate of prosopagnosia in semantic dementia
    K A Josephs
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 71:1628-33. 2008
    ..To determine the anatomic correlate of prosopagnosia in subjects with semantic dementia...
  52. pmc Effects of age on the glucose metabolic changes in mild cognitive impairment
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    AJNR Am J Neuroradiol 31:1247-53. 2010
    ..Decreased glucose metabolism in the temporal and parietal lobes on FDG-PET is recognized as an early imaging marker for the AD pathology. Our objective was to investigate the effects of age on FDG-PET findings in aMCI...
  53. pmc Imaging correlates of pathology in corticobasal syndrome
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Neurology 75:1879-87. 2010
    ..The aim of this study was to determine whether patterns of atrophy on imaging could be useful to help predict underlying pathology in CBS...
  54. ncbi Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy
    D F Tang-Wai
    Department of Neurology, Mayo Alzheimer s Disease Research Center, Rochester, MN, USA
    Neurology 63:1168-74. 2004
    ..To examine the clinical, genetic, and neuropathologic features of posterior cortical atrophy (PCA)...
  55. pmc 1H MR spectroscopy in common dementias
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    Neurology 63:1393-8. 2004
    ..To determine the 1H MR spectroscopic (MRS) findings and intergroup differences among common dementias: Alzheimer disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD)...
  56. pmc MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study
    J L Whitwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurology 71:743-9. 2008
    ..We aimed to determine whether patterns of gray matter atrophy from antemortem MRI correlate with Braak staging of NFT pathology...
  57. pmc Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI
    K Kantarci
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 74:1814-21. 2010
    ....
  58. pmc Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?
    J L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 75:2212-20. 2010
    ..To determine whether TDP-43 type is associated with distinct patterns of brain atrophy on MRI in subjects with pathologically confirmed frontotemporal lobar degeneration (FTLD)...
  59. ncbi Incident dementia in women is preceded by weight loss by at least a decade
    D S Knopman
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 69:739-46. 2007
    ..Although several studies reported weight loss preceding the onset of dementia, other studies suggested that obesity in midlife or even later in life may be a risk factor for dementia...
  60. ncbi Normative data for the Mattis Dementia Rating Scale
    J A Lucas
    Department of Psychiatry and Psychology, Mayo Foundation, Rochester, MN, USA
    J Clin Exp Neuropsychol 20:536-47. 1998
    ..Limitations and unique features of MOANS normative data are also discussed...
  61. pmc Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN
    J L Whitwell
    Department of Radiology Research, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 72:813-20. 2009
    ..To compare patterns of gray matter loss in subjects with mutations in the progranulin (PGRN) gene to subjects with mutations in the microtubule-associated protein tau (MAPT) gene...
  62. pmc Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 58:750-7. 2002
    ....
  63. ncbi Diagnostic accuracy of four approaches to interpreting neuropsychological test data
    R J Ivnik
    Psychology Division, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neuropsychology 14:163-77. 2000
    ..0 (i.e., chance) to 34.9. The clinical usefulness of absolute scores and difference scores in data interpretation is supported. Neither profile variability measures nor measures of change over time were diagnostically useful...
  64. pmc Mild cognitive impairment and Alzheimer disease: regional diffusivity of water
    K Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 219:101-7. 2001
    ..Elevation in hippocampal ADC may reflect early ultrastructural changes in the progression of Alzheimer disease...
  65. pmc Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
    C R Jack
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neurology 49:786-94. 1997
    ..99 SD, and moderate AD (CDR 2) -2.22 SD. Age- and gender-adjusted, normalized MRI-based hippocampal volumetric measurements provide a sensitive marker of the MTL neuroanatomic degeneration in AD early in the disease process...
  66. ncbi Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia
    K A Josephs
    Department of Neurology, Division of Behavioural Neurology, Mayo Clinic, Mayo Foundation, Rochester, MN 55905, USA
    Neurocase 11:283-96. 2005
    ..These cases demonstrate that atypical PSP can present as AOS and PNFA without the classic features of PSP...
  67. pmc Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults
    Kejal Kantarci
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 77:951-8. 2011
    ....
  68. ncbi Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia
    Gregory A Jicha
    Alzheimer s Disease Research Center and Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:674-81. 2006
    ..The pathologic outcome of patients diagnosed with mild cognitive impairment (MCI) following progression to dementia is poorly understood...
  69. pmc Prominent phenotypic variability associated with mutations in Progranulin
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurobiol Aging 30:739-51. 2009
    ..Some kindreds with PGRN mutations exhibited lateralized topography of degeneration across all affected individuals...
  70. pmc Progressive aphasia secondary to Alzheimer disease vs FTLD pathology
    K A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 70:25-34. 2008
    ..The pathology causing progressive aphasia is typically a variant of frontotemporal lobar degeneration, especially with ubiquitin-positive inclusions (FTLD-U). Less commonly the underlying pathology is Alzheimer disease (AD)...
  71. ncbi Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans
    D Sencakova
    Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, Minn, USA
    Arch Neurol 58:1593-7. 2001
    ..The neuropsychological-hippocampal volume correlations indicate that hippocampal volume measurements do represent a measure of the structural substrate of functional impairment in AD...
  72. pmc Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients
    M M Machulda
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 61:500-6. 2003
    ..To determine whether an fMRI memory encoding task distinguishes among cognitively normal elderly individuals, patients with mild cognitive impairment (MCI), and patients with early Alzheimer's disease (AD)...
  73. ncbi Mayo's older Americans normative studies: category fluency norms
    J A Lucas
    Department of Psychiatry and Psychology, Mayo Foundation, Rochester, MN, USA
    J Clin Exp Neuropsychol 20:194-200. 1998
    ..Limitations and unique features of MOANS normative data are also discussed...
  74. ncbi Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND
    K A Josephs
    Department of Neurology, Mayo Clinic, 200 First St S W, Rochester, MN 55905, USA
    Neurology 65:645-7. 2005
    ..An analysis of patient outcomes in these cases reveals that FTLD-MND has significantly shorter survival than FTLD-U, suggesting that FTLD-MND is a more aggressive disease process...
  75. ncbi Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease
    D S Knopman
    The Mayo Alzheimer Disease Research Center, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Neurology 65:986-90. 2005
    ..To study coronary artery bypass grafting (CABG) as a risk factor for dementia and Alzheimer disease (AD) using a case-control design...
  76. ncbi Confrontation naming does not add incremental diagnostic utility in MCI and Alzheimer's disease
    Julie A Testa
    Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Int Neuropsychol Soc 10:504-12. 2004
    ..Collectively these results suggest that although BNT impairments become more common as AD progresses, they are neither necessary for the diagnosis of AD nor particularly useful in identifying early AD...
  77. pmc Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
    Prashanthi Vemuri
    Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Ann Neurol 67:308-16. 2010
    ....
  78. pmc Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
    Joseph L Price
    Department of Anatomy and Neurobiology, Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, MO, USA
    Neurobiol Aging 30:1026-36. 2009
    ..To determine the frequency and possible cognitive effect of histological Alzheimer's disease (AD) in autopsied older nondemented individuals...
  79. ncbi Vitamin E and donepezil for the treatment of mild cognitive impairment
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    N Engl J Med 352:2379-88. 2005
    ..Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease...
  80. pmc Rates of cerebral atrophy differ in different degenerative pathologies
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Brain 130:1148-58. 2007
    ....
  81. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  82. ncbi Neurofilament inclusion body disease: a new proteinopathy?
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Brain 126:2291-303. 2003
    ..We propose the term neurofilament inclusion body disease for this entity...
  83. pmc 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Brain 130:1777-86. 2007
    ..These results also suggest that 3D patterns of grey matter atrophy may help to predict the time to the first diagnosis of AD in subjects with aMCI...
  84. pmc Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin
    Brendan J Kelley
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 67:171-7. 2010
    ..To characterize a kindred with a familial neurodegenerative disorder associated with a mutation in progranulin (PGRN), with emphasis on the unique clinical features in this kindred...
  85. pmc The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80
    Selam Negash
    Department of Neurology, Mayo Clinic, USA
    Neuropsychology 23:81-9. 2009
    ..The dissipation of the APOE effect in old-old individuals at lower risk of AD suggests that visuospatial attention impairments seen as early as midlife in APOE-e4 carriers may be a preclinical marker of AD...
  86. pmc Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minn, USA
    Dement Geriatr Cogn Disord 14:198-207. 2002
    ..Selection of imaging measures used for clinical assessment or monitoring efficiency of therapeutic intervention should be tailored to the clinical stage of the disease...
  87. pmc 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease
    Kejal Kantarci
    Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Int Neuropsychol Soc 8:934-42. 2002
    ..Among 1H-MRS measurements, the NAA/MI ratio maybe the most efficient predictor of memory and cognitive function in patients with MCI and AD...
  88. ncbi Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    J Neuropathol Exp Neurol 66:142-51. 2007
    ..On the other hand, there is no histopathologic feature or combination of features that is pathognomonic. Neuronal intranuclear inclusions are virtually always present, but they can be detected in PGRN(-) cases...
  89. pmc Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase
    Jing He
    Department of Neurology, University of California at Davis, Sacramento, CA 95817, USA
    Arch Neurol 67:1231-7. 2010
    ....
  90. pmc Replication of CLU, CR1, and PICALM associations with alzheimer disease
    Minerva M Carrasquillo
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Rd, Birdsall Building, Jacksonville, FL 32224, USA
    Arch Neurol 67:961-4. 2010
    ..To test for replication of the association between variants in the CLU, CR1, and PICALM genes with Alzheimer disease...
  91. pmc Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations
    Jennifer L Whitwell
    Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:371-6. 2007
    ..Mutations in the progranulin gene (PGRN) have recently been identified as a cause of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) in some families...
  92. doi Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome
    William T Hu
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Mov Disord 24:1375-9. 2009
    ..AD patients with clinical CBS have similar characteristics to CBD patients. Functional brain imaging may have greater utility than the clinical and neuropsychological features in differentiating AD presenting as CBS from CBD...
  93. pmc Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members
    NiCole Finch
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Brain 132:583-91. 2009
    ..We propose that plasma GRN levels could be used as a reliable and inexpensive tool to identify all GRN mutation carriers in early-onset dementia populations and asymptomatic at-risk individuals...
  94. pmc Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Brain 130:708-19. 2007
    ..Damage to this network of structures in DLB may affect a number of different neurotransmitter systems which in turn may contribute to a number of the core clinical features of DLB...
  95. pmc Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease
    Matthew L Senjem
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Neuroimage 26:600-8. 2005
    ....
  96. pmc Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease
    Jennifer L Whitwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Neuroimage 39:1034-40. 2008
    ..The trajectories of brain and ventricular changes were similar in AD and FTLD-U suggesting that it is independent of pathology, although subjects with FTLD-U show a more rapidly progressive decline...
  97. pmc Age and apoE associations with complex pathologic features in Alzheimer's disease
    Gregory A Jicha
    Department of Neurology, Mayo Clinic, Rochester, MN, Jacksonville, FL, United States
    J Neurol Sci 273:34-9. 2008
    ....
  98. ncbi Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment
    Gregory A Jicha
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Neuropathol Exp Neurol 65:602-9. 2006
    ..AGD is a common pathologic finding in subjects who have been diagnosed with amnestic MCI...
  99. ncbi Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort
    Yoko Miyasaka
    Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Eur Heart J 28:1962-7. 2007
    ..To estimate the incidence of dementia after the first atrial fibrillation (AF), and its impact on survival in a community-based cohort...
  100. pmc Functional impact of white matter hyperintensities in cognitively normal elderly subjects
    Melissa E Murray
    Department of Neuroscience Neuropathology, Mayo Clinic, Jacksonville, Florida, USA
    Arch Neurol 67:1379-85. 2010
    ..To investigate the impact white matter hyperintensities (WMH) detected on magnetic resonance imaging have on motor dysfunction and cognitive impairment in elderly subjects without dementia...
  101. ncbi Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction
    D F Tang-Wai
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 61:1134-5. 2003
    ..Underlying CBD should be considered in the differential diagnosis of patients with findings reflecting posterior cerebral dysfunction...

Research Grants3

  1. ALZHEIMER DISEASE PATIENT REGISTRY
    Ronald Petersen; Fiscal Year: 2007
    ..This population-based cohort will be a valuable resource for additional research on epidemiology, clinical characteristics, neuropsychological features, neuroimaging measures, and neuropathological substrate of prodromal dementia. ..